ANI Pharmaceuticals
ANIP
Market cap $1.31B

60.64 USD

+0.48

0.80%

At close May 20, 4:00 PM EDT

After hours

60.64

+0.00

0.00%

1 day

0.80%

5 days

-2.56%

1 month

-10.82%

3 months

1.63%

6 months

10.05%

Year to date

9.38%

1 year

-1.77%

5 years

92.51%

10 years

17.68%

About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Employees: 897

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,202 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

119% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 21

26% more capital invested

Capital invested by funds: $1.07B [Q4 2024] → $1.34B (+$278M) [Q1 2025]

10% more funds holding

Funds holding: 204 [Q4 2024] → 224 (+20) [Q1 2025]

0.19% less ownership

Funds ownership: 91.71% [Q4 2024] → 91.52% (-0.19%) [Q1 2025]

10% less repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 71

38% less call options, than puts

Call options by funds: $535K | Put options by funds: $863K

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$65

7%

upside

Avg. target

$82

35%

upside

High target

$94

55%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Guggenheim Vamil Divan	42%upside $86	Buy Reiterated	12 May 2025
Truist Securities Gregory Fraser	7%upside $65	Hold Maintained	21 Apr 2025
HC Wainwright & Co. Oren Livnat	55%upside $94	Buy Reiterated	17 Mar 2025
Jefferies Glen Santangelo	32%upside $80	Buy Initiated	14 Mar 2025
JP Morgan Ekaterina Knyazkova	40%upside $85	Overweight Initiated	12 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 17 articles about ANIP published over the past 30 days

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows:

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

Zacks Investment Research

ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why

ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by.

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.21 per share a year ago.

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2025.

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals: A Short-Term Buying Opportunity

ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion and $350 million respectively, driving ANIP's PPS higher.

ANI Pharmaceuticals: A Short-Term Buying Opportunity

Zacks Investment Research

ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?

ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.

ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?

Zacks Investment Research

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

See News Rankings

Charts implemented using Lightweight Charts™